These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma? Sasaki M; Sato Y; Nakanuma Y Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959 [TBL] [Abstract][Full Text] [Related]
3. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA. Wang C; Chen C; Hu W; Tao L; Chen J Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206 [TBL] [Abstract][Full Text] [Related]
4. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. Murugesan K; Sharaf R; Montesion M; Moore JA; Pao J; Pavlick DC; Frampton GM; Upadhyay VA; Alexander BM; Miller VA; Javle MM; Bekaii Saab TS; Albacker LA; Ross JS; Ali SM JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476330 [TBL] [Abstract][Full Text] [Related]
5. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study. Sasaki M; Sato Y; Nakanuma Y Virchows Arch; 2024 Jun; 484(6):915-923. PubMed ID: 38532197 [TBL] [Abstract][Full Text] [Related]
7. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role. Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258 [TBL] [Abstract][Full Text] [Related]
8. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification. Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585 [TBL] [Abstract][Full Text] [Related]
9. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764 [TBL] [Abstract][Full Text] [Related]
10. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology. Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845 [TBL] [Abstract][Full Text] [Related]
12. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787 [No Abstract] [Full Text] [Related]
13. Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality. Na HY; Kim JH; Kim H; Cho JY; Han HS; Jang ES; Kim JW; Jeong SH; Heo J; Kim JW; Kim JW; Ahn S Histopathology; 2024 Jan; 84(2):402-408. PubMed ID: 37903726 [TBL] [Abstract][Full Text] [Related]
14. Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort. Teufel A; Rodriguez I; Winzler C; Kokh D; Ebert MP; Surovtsova I; Morakis P J Gastrointestin Liver Dis; 2023 Jun; 32(2):190-196. PubMed ID: 37345609 [TBL] [Abstract][Full Text] [Related]
15. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274 [TBL] [Abstract][Full Text] [Related]
16. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009-2021). Terai K; Ishigaki K; Kagawa Y; Okada K; Yoshida O; Sakurai N; Heishima T; Asano K J Am Vet Med Assoc; 2022 Apr; 260(13):1668-1674. PubMed ID: 35482569 [TBL] [Abstract][Full Text] [Related]
17. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Lee HS; Kim MJ; An C Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477 [TBL] [Abstract][Full Text] [Related]
19. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas. Patil PA; Taddei T; Jain D; Zhang X Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854 [TBL] [Abstract][Full Text] [Related]
20. Implications of ultrasound-based deep learning model for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Chen J; Zhang W; Bao J; Wang K; Zhao Q; Zhu Y; Chen Y Abdom Radiol (NY); 2024 Jan; 49(1):93-102. PubMed ID: 37999743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]